Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy

References

• Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain J Neurol. 1952;75:408–427.
   Google Scholar
• Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34:520–528.
   PubMed Web of Science ®Google Scholar
• Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341:1113–1116.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–792.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Sekijima Y, et al. The Diflunisal Trial: study accrual and drug tolerance. Amyloid. 2012;19 Suppl 1:37–38.
   PubMed Web of Science ®Google Scholar
• Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
   PubMed Web of Science ®Google Scholar
• Adams D, Cauquil C, Theaudin M, et al. Current and future treatment of amyloid neuropathies. Expert Rev Neurother. 2014;14:1437–1451.
   PubMed Web of Science ®Google Scholar
• Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain J Neurol. 2000;123:1495–1504.
   Google Scholar
• Yamamoto S, Wilczek HE, Nowak G, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): A single‐center experience over 16 years. Am J Transplant. 2007;7:2597–2604.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78:637–643.
   PubMed Web of Science ®Google Scholar
• Wilczek HE, Larsson M, Ericzon B-G, et al. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid. 2011;18:193–195.
   PubMed Web of Science ®Google Scholar
• Herlenius G, Wilczek HE, Larsson M, et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry. Transplantation. 2004;77:64–71.
   PubMed Web of Science ®Google Scholar
• Algalarrondo V, Antonini T, Théaudin M, et al. Cardiac dysautonomia predicts long-term survival in hereditary transthyretin amyloidosis after liver transplantation. JACC Cardiovasc Imaging. 2016;9:1432–1441.
   PubMed Web of Science ®Google Scholar
• Algalarrondo V, Antonini T, Théaudin M, et al. Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2154–2156.
   PubMed Web of Science ®Google Scholar
• Denier C, Ducot B, Husson H, et al. A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy. J Neurol. 2007;254:1684–1688.
   PubMed Web of Science ®Google Scholar
• Antonini TM, Lozeron P, Lacroix C, et al. Reversibility of acquired amyloid polyneuropathy after liver retransplantation. Am J Transplant. 2013;13:2734–2738.
   PubMed Web of Science ®Google Scholar
• Suhr O, Danielsson A, Holmgren G, et al. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994;235:479–485.
   PubMed Web of Science ®Google Scholar
• Algalarrondo V, Dinanian S, Juin C, et al. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Heart Rhythm. 2012;9:1069–1075.
   PubMed Web of Science ®Google Scholar
• Delahaye N, Dinanian S, Slama MS, et al. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur J Nucl Med. 1999;26:416–424.
   PubMedGoogle Scholar
• Coutinho MCA, Cortez-Dias N, Cantinho G, et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging. 2013;6:627–636.
   PubMed Web of Science ®Google Scholar
• Mariani L, Lozeron P, Theaudin M, et al. Genotype-phenotype correlation and course of TTR familial amyloid polyneuropathies in France. Ann Neurol. 2015;
   PubMed Web of Science ®Google Scholar
• Johnston SD, Morris JK, Cramb R, et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation. 2002;73:901–906.
   PubMed Web of Science ®Google Scholar
• Suhr OB, Larsson M, Ericzon B-G, et al. Survival after transplantation in patients with mutations other than Val30Met: extracts from the FAP World Transplant Registry. Transplantation. 2016;100:373.
   PubMed Web of Science ®Google Scholar
• Ericzon B-G, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;1:
   Google Scholar
• Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33:1120–1127.
   PubMed Web of Science ®Google Scholar
• Nelson LM, Penninga L, Villadsen GE, et al. Outcome in patients treated with isolated liver transplantation for familial transthyretin amyloidosis to prevent cardiomyopathy. Clin Transplant. 2015;29:1098–1104.
   PubMed Web of Science ®Google Scholar
• Yazaki M, Mitsuhashi S, Tokuda T, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant. 2007;7:235–242.
   PubMed Web of Science ®Google Scholar
• Okamoto S, Zhao Y, Lindqvist P, et al. Development of cardiomyopathy after liver transplantation in Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid. 2011;18:200–205.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Yazaki M, Oguchi K, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87:773–781.
   PubMed Web of Science ®Google Scholar
• Salvi F, Pastorelli F, Plasmati R, et al. Brain microbleeds 12 years after orthotopic liver transplantation in Val30Met amyloidosis. J Stroke Cerebrovasc Dis. 2015;24:e149–e151.
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Cardiac dysautonomia and survival in hereditary transthyretin amyloidosis. JACC Cardiovasc Imaging. 2016; 9:1442–1445.
   PubMed Web of Science ®Google Scholar